Published in Clin Cancer Res on January 26, 2010
microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer. Oncogene (2011) 3.02
The role of microRNAs in human liver cancers. Semin Oncol (2011) 1.34
miR-193b Regulates Mcl-1 in Melanoma. Am J Pathol (2011) 1.09
Carboxyl-terminal truncated HBx regulates a distinct microRNA transcription program in hepatocellular carcinoma development. PLoS One (2011) 1.05
Hepatitis B virus X protein downregulates expression of the miR-16 family in malignant hepatocytes in vitro. Br J Cancer (2011) 1.05
MicroRNA-193b-3p acts as a tumor suppressor by targeting the MYB oncogene in T-cell acute lymphoblastic leukemia. Leukemia (2014) 1.02
HCV core protein-induced down-regulation of microRNA-152 promoted aberrant proliferation by regulating Wnt1 in HepG2 cells. PLoS One (2014) 0.95
Towards incorporating epigenetic mechanisms into carcinogen identification and evaluation. Carcinogenesis (2013) 0.92
miRNAs affect the development of hepatocellular carcinoma via dysregulation of their biogenesis and expression. Cell Commun Signal (2014) 0.91
microRNAs in liver disease: from diagnostics to therapeutics. Clin Biochem (2013) 0.91
Cholinesterase-Targeting microRNAs Identified in silico Affect Specific Biological Processes. Front Mol Neurosci (2011) 0.90
Serum MicroRNAs as Potential Biomarkers for Early Diagnosis of Hepatitis C Virus-Related Hepatocellular Carcinoma in Egyptian Patients. PLoS One (2015) 0.86
The role of Merkel cell polyomavirus and other human polyomaviruses in emerging hallmarks of cancer. Viruses (2015) 0.85
Non-Coding RNAs in Primary Liver Cancer. Front Med (Lausanne) (2015) 0.85
The microRNAs as potential biomarkers for predicting the onset of aflatoxin exposure in human beings: a review. Front Microbiol (2014) 0.84
MicroRNAs and hepatitis C virus: toward the end of miR-122 supremacy. Virol J (2012) 0.84
Hepatitis C virus core protein down-regulates p21(Waf1/Cip1) and inhibits curcumin-induced apoptosis through microRNA-345 targeting in human hepatoma cells. PLoS One (2013) 0.84
Integrative genomics identifies candidate microRNAs for pathogenesis of experimental biliary atresia. BMC Syst Biol (2013) 0.83
Complex interactions between microRNAs and hepatitis B/C viruses. World J Gastroenterol (2014) 0.83
MicroRNA expression profiling in PBMCs: a potential diagnostic biomarker of chronic hepatitis C. Dis Markers (2014) 0.83
MicroRNA expression analysis in high fat diet-induced NAFLD-NASH-HCC progression: study on C57BL/6J mice. BMC Cancer (2016) 0.81
MicroRNA gene dosage alterations and drug response in lung cancer. J Biomed Biotechnol (2011) 0.81
microRNA levels in paraffin-embedded indolent B-cell non-Hodgkin lymphoma tissues from patients chronically infected with hepatitis B or C virus. BMC Infect Dis (2014) 0.81
Specific Roles of MicroRNAs in Their Interactions with Environmental Factors. J Nucleic Acids (2012) 0.80
MicroRNA expression in hepatitis C virus-related malignancies: A brief review. World J Gastroenterol (2015) 0.79
miR-21 expression and clinical outcome in locally advanced pancreatic cancer: exploratory analysis of the pancreatic cancer Erbitux, radiotherapy and UFT (PERU) trial. Oncotarget (2016) 0.79
Relation between microRNAs and Apoptosis in Hepatocellular Carcinoma. Open Access Maced J Med Sci (2016) 0.77
Wnt signalling modulates transcribed-ultraconserved regions in hepatobiliary cancers. Gut (2016) 0.76
Bioinformatics approach to predict target genes for dysregulated microRNAs in hepatocellular carcinoma: study on a chemically-induced HCC mouse model. BMC Bioinformatics (2015) 0.75
Exceptional serological and radiological response to sorafenib in 2 patients with advanced hepatocellular carcinoma and chronic hepatitis C viral infection: case report and review of the literature. BMC Gastroenterol (2017) 0.75
MicroRNA and hepatitis C virus--challenges in investigation and translation: a review of the literature. Diagn Microbiol Infect Dis (2014) 0.75
Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets. Cell (2005) 96.87
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
Combinatorial microRNA target predictions. Nat Genet (2005) 50.48
A mammalian microRNA expression atlas based on small RNA library sequencing. Cell (2007) 34.03
Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology (2007) 26.78
Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA. Science (2005) 16.84
A pattern-based method for the identification of MicroRNA binding sites and their corresponding heteroduplexes. Cell (2006) 14.70
Genetic variation in IL28B and spontaneous clearance of hepatitis C virus. Nature (2009) 13.99
MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology (2007) 13.20
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol (2006) 10.21
Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology (2006) 7.06
Interferon modulation of cellular microRNAs as an antiviral mechanism. Nature (2007) 7.04
mir-29 regulates Mcl-1 protein expression and apoptosis. Oncogene (2007) 7.02
Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol (2006) 6.95
Cellular cofactors affecting hepatitis C virus infection and replication. Proc Natl Acad Sci U S A (2007) 6.79
Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues. Oncogene (2006) 6.61
miRBase: the microRNA sequence database. Methods Mol Biol (2006) 6.17
Cyclin G1 is a target of miR-122a, a microRNA frequently down-regulated in human hepatocellular carcinoma. Cancer Res (2007) 5.40
Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology (2008) 4.73
MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity. Cancer Res (2009) 3.83
RNAi as random degradative PCR: siRNA primers convert mRNA into dsRNAs that are degraded to generate new siRNAs. Cell (2001) 3.80
Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res (2008) 3.67
Apoptosis induced by the kinase inhibitor BAY 43-9006 in human leukemia cells involves down-regulation of Mcl-1 through inhibition of translation. J Biol Chem (2005) 3.08
MicroRNAs modulate the chemosensitivity of tumor cells. Mol Cancer Ther (2008) 3.06
MicroRNA gene expression profile of hepatitis C virus-associated hepatocellular carcinoma. Hepatology (2008) 3.00
The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006. Oncogene (2005) 2.89
Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J Virol (2008) 2.74
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
Unique biology of Mcl-1: therapeutic opportunities in cancer. Curr Mol Med (2008) 2.22
Genetic mechanisms of hepatocarcinogenesis. Oncogene (2002) 2.21
Inhibition of interleukin 6-mediated mitogen-activated protein kinase activation attenuates growth of a cholangiocarcinoma cell line. Hepatology (1999) 2.20
A methodology for the combined in situ analyses of the precursor and mature forms of microRNAs and correlation with their putative targets. Nat Protoc (2009) 1.85
Mcl-1 overexpression in hepatocellular carcinoma: a potential target for antisense therapy. J Hepatol (2005) 1.77
Hepatitis C virus triggers apoptosis of a newly developed hepatoma cell line through antiviral defense system. Gastroenterology (2007) 1.75
Suppression of Mcl-1 via RNA interference sensitizes human hepatocellular carcinoma cells towards apoptosis induction. BMC Cancer (2006) 1.35
Hepatitis C virus core protein is a potent inhibitor of RNA silencing-based antiviral response. Gastroenterology (2006) 1.31
Gene expression profiling of human HBV- and/or HCV-associated hepatocellular carcinoma cells using expressed sequence tags. Int J Oncol (2006) 1.26
Mcl-1 is an anti-apoptotic factor for human hepatocellular carcinoma. Int J Oncol (2006) 1.20
In situ simultaneous detection of hepatitis C virus RNA and hepatitis C virus-related antigens in hepatocellular carcinoma. Cancer (1997) 1.06
Responses of nontransformed human hepatocytes to conditional expression of full-length hepatitis C virus open reading frame. Am J Pathol (2007) 0.96
siRNA-mediated Bcl-2 and Bcl-xl gene silencing sensitizes human hepatoblastoma cells to chemotherapeutic drugs. Clin Exp Pharmacol Physiol (2007) 0.95
Hepatic gene expression profiles associated with fibrosis progression and hepatocarcinogenesis in hepatitis C patients. World J Gastroenterol (2005) 0.92
Cellular plasticity of trans- and dedifferentiation markers in human hepatoma cells in vitro and in vivo. Int J Oncol (2009) 0.89
Expression profiling of liver cell lines expressing entire or parts of hepatitis C virus open reading frame. Hepatology (2002) 0.88
Suppression of interferon-induced antiviral activity in cells expressing hepatitis C virus proteins. J Interferon Cytokine Res (2000) 0.83
Expression of stem cell factor receptor c-kit in human nontumoral and tumoral hepatic cells. Eur J Gastroenterol Hepatol (2009) 0.82
Hepatocellular carcinoma in patients with hepatitis C virus-related chronic liver disease. World J Gastroenterol (2007) 0.79
Immunoperoxidase staining of hepatitis C virus in formalin-fixed, paraffin-embedded needle liver biopsies. Virchows Arch (1994) 0.77
MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology (2007) 13.20
MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA (2007) 9.97
MicroRNA signatures in human ovarian cancer. Cancer Res (2007) 9.45
Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol (2007) 8.05
MicroRNA-cancer connection: the beginning of a new tale. Cancer Res (2006) 7.38
Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines. Gastroenterology (2006) 7.06
Relation between microRNA expression and progression and prognosis of gastric cancer: a microRNA expression analysis. Lancet Oncol (2009) 5.56
Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell (2007) 5.40
Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res (2008) 4.64
miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell (2009) 4.48
MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A (2008) 4.33
Surgical treatment of permanent diaphragm paralysis after interscalene nerve block for shoulder surgery. Anesthesiology (2013) 4.25
MicroRNAs regulate critical genes associated with multiple myeloma pathogenesis. Proc Natl Acad Sci U S A (2008) 3.77
MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer (2007) 3.53
Downregulation of p53-inducible microRNAs 192, 194, and 215 impairs the p53/MDM2 autoregulatory loop in multiple myeloma development. Cancer Cell (2010) 3.52
Vesiclepedia: a compendium for extracellular vesicles with continuous community annotation. PLoS Biol (2012) 3.18
MicroRNA-122 inhibits tumorigenic properties of hepatocellular carcinoma cells and sensitizes these cells to sorafenib. J Biol Chem (2009) 3.16
Association of a microRNA/TP53 feedback circuitry with pathogenesis and outcome of B-cell chronic lymphocytic leukemia. JAMA (2011) 3.16
Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem (2008) 3.00
Intercellular nanovesicle-mediated microRNA transfer: a mechanism of environmental modulation of hepatocellular cancer cell growth. Hepatology (2011) 2.90
Interaction of hepatitis C virus nonstructural protein 5A with core protein is critical for the production of infectious virus particles. J Virol (2008) 2.74
Interleukin-1beta selectively expands and sustains interleukin-22+ immature human natural killer cells in secondary lymphoid tissue. Immunity (2010) 2.67
Reprogramming of miRNA networks in cancer and leukemia. Genome Res (2010) 2.65
MicroRNA-451 regulates LKB1/AMPK signaling and allows adaptation to metabolic stress in glioma cells. Mol Cell (2010) 2.59
Degos disease: a C5b-9/interferon-α-mediated endotheliopathy syndrome. Am J Clin Pathol (2011) 2.50
EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med (2011) 2.46
Role of microRNA-155 at early stages of hepatocarcinogenesis induced by choline-deficient and amino acid-defined diet in C57BL/6 mice. Hepatology (2009) 2.29
MiR-199a-3p regulates mTOR and c-Met to influence the doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res (2010) 2.28
MicroRNA-dependent regulation of DNA methyltransferase-1 and tumor suppressor gene expression by interleukin-6 in human malignant cholangiocytes. Hepatology (2010) 2.23
Stage 3 immature human natural killer cells found in secondary lymphoid tissue constitutively and selectively express the TH 17 cytokine interleukin-22. Blood (2009) 2.18
Epigenetic regulation of miR-17~92 contributes to the pathogenesis of pulmonary fibrosis. Am J Respir Crit Care Med (2013) 2.16
MiR-122/cyclin G1 interaction modulates p53 activity and affects doxorubicin sensitivity of human hepatocarcinoma cells. Cancer Res (2009) 2.16
MicroRNAs in the pathogenesis of cancer. Semin Oncol (2011) 2.15
Modulation of mismatch repair and genomic stability by miR-155. Proc Natl Acad Sci U S A (2010) 2.05
MicroRNA-21 induces resistance to 5-fluorouracil by down-regulating human DNA MutS homolog 2 (hMSH2). Proc Natl Acad Sci U S A (2010) 1.99
HMGA2 induces pituitary tumorigenesis by enhancing E2F1 activity. Cancer Cell (2006) 1.96
MicroRNA cluster 221-222 and estrogen receptor alpha interactions in breast cancer. J Natl Cancer Inst (2010) 1.94
The MicroRNA let-7a modulates interleukin-6-dependent STAT-3 survival signaling in malignant human cholangiocytes. J Biol Chem (2007) 1.90
Hepatitis C virus RNA replication is regulated by FKBP8 and Hsp90. EMBO J (2006) 1.89
Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proc Natl Acad Sci U S A (2010) 1.87
Specific activation of microRNA106b enables the p73 apoptotic response in chronic lymphocytic leukemia by targeting the ubiquitin ligase Itch for degradation. Blood (2008) 1.87
Human VAP-B is involved in hepatitis C virus replication through interaction with NS5A and NS5B. J Virol (2005) 1.86
A pilot study evaluating the safety and efficacy of OP-1 Putty (rhBMP-7) as a replacement for iliac crest autograft in posterolateral lumbar arthrodesis for degenerative spondylolisthesis. Spine (Phila Pa 1976) (2004) 1.86
MicroRNA-221 targets Bmf in hepatocellular carcinoma and correlates with tumor multifocality. Clin Cancer Res (2009) 1.84
Utility of the Mayo End-Stage Liver Disease (MELD) score in assessing prognosis of patients with alcoholic hepatitis. BMC Gastroenterol (2002) 1.83
Interleukin-6 contributes to growth in cholangiocarcinoma cells by aberrant promoter methylation and gene expression. Cancer Res (2006) 1.80
Proteasome activator PA28gamma-dependent nuclear retention and degradation of hepatitis C virus core protein. J Virol (2003) 1.76
Are common factors involved in the pathogenesis of primary liver cancers? A meta-analysis of risk factors for intrahepatic cholangiocarcinoma. J Hepatol (2012) 1.74
Evidence for a stepwise program of extrathymic T cell development within the human tonsil. J Clin Invest (2012) 1.72
Genomics of chronic lymphocytic leukemia microRNAs as new players with clinical significance. Semin Oncol (2006) 1.71
Proteomic profiling of lipid droplet proteins in hepatoma cell lines expressing hepatitis C virus core protein. J Biochem (2006) 1.71
Karyotype-specific microRNA signature in chronic lymphocytic leukemia. Blood (2009) 1.70
Over-expression of interleukin-6 enhances cell survival and transformed cell growth in human malignant cholangiocytes. J Hepatol (2005) 1.69
Critical role of virion-associated cholesterol and sphingolipid in hepatitis C virus infection. J Virol (2008) 1.65
A randomized, double-blinded, placebo-controlled multicenter trial of etanercept in the treatment of alcoholic hepatitis. Gastroenterology (2008) 1.65
Gene expression networks in COPD: microRNA and mRNA regulation. Thorax (2011) 1.62
Pathogenesis of lipid metabolism disorder in hepatitis C: polyunsaturated fatty acids counteract lipid alterations induced by the core protein. J Hepatol (2010) 1.58
Preoperative evaluation of patients with liver disease. Nat Clin Pract Gastroenterol Hepatol (2007) 1.56
REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin Cancer Res (2010) 1.53
Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. Carcinogenesis (2010) 1.52
miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res (2011) 1.51
Extracellular Vesicle-Mediated Transfer of a Novel Long Noncoding RNA TUC339: A Mechanism of Intercellular Signaling in Human Hepatocellular Cancer. Genes Cancer (2013) 1.47
Racial and ethnic variations in the epidemiology of intrahepatic cholangiocarcinoma in the United States. Liver Int (2006) 1.45
Critical role of PA28gamma in hepatitis C virus-associated steatogenesis and hepatocarcinogenesis. Proc Natl Acad Sci U S A (2007) 1.45
miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia. Blood (2011) 1.44
Integrated microRNA and mRNA signatures associated with survival in triple negative breast cancer. PLoS One (2013) 1.43
Complete clinical response of metastatic hepatocellular carcinoma to sorafenib in a patient with hemochromatosis: a case report. J Hematol Oncol (2008) 1.43
MicroRNA expression profiling: a molecular tool for defining the phenotype of hepatocellular tumors. Hepatology (2008) 1.43
Human herpesvirus 6-related fulminant myocarditis and hepatitis in an immunocompetent adult with fatal outcome. Hum Pathol (2009) 1.42
Bovine leukemia virus DNA in human breast tissue. Emerg Infect Dis (2014) 1.41
miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED. Cancer Res (2010) 1.36
The role of microRNAs in human liver cancers. Semin Oncol (2011) 1.34
Expression profiling of microRNA using oligo DNA arrays. Methods (2008) 1.31
Molecular determinants for subcellular localization of hepatitis C virus core protein. J Virol (2005) 1.31
Interaction of hepatitis C virus core protein with retinoid X receptor alpha modulates its transcriptional activity. Hepatology (2002) 1.30
Comprehensive miRNA profiling of surgically staged endometrial cancer. Am J Obstet Gynecol (2010) 1.30
Aberrant regulation of pVHL levels by microRNA promotes the HIF/VEGF axis in CLL B cells. Blood (2009) 1.29
microRNA expression profiling identifies a four microRNA signature as a novel diagnostic and prognostic biomarker in triple negative breast cancers. Oncotarget (2014) 1.28
Identifying opportunities for improved colorectal cancer screening in primary care. Prev Med (2004) 1.26
Replication of hepatitis C virus genotype 3a in cultured cells. Gastroenterology (2012) 1.25
Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal. J Biol Chem (2011) 1.24
Estrogen mediated-activation of miR-191/425 cluster modulates tumorigenicity of breast cancer cells depending on estrogen receptor status. PLoS Genet (2013) 1.24
Intramembrane processing by signal peptide peptidase regulates the membrane localization of hepatitis C virus core protein and viral propagation. J Virol (2008) 1.23
Long noncoding RNA in liver diseases. Hepatology (2014) 1.23
MicroRNAs in diseases and drug response. Curr Opin Pharmacol (2008) 1.23